Edition:
United Kingdom

Audentes Therapeutics Inc (BOLD.OQ)

BOLD.OQ on NASDAQ Stock Exchange Global Market

22.49USD
14 Nov 2018
Change (% chg)

$-1.01 (-4.30%)
Prev Close
$23.50
Open
$23.50
Day's High
$23.73
Day's Low
$22.33
Volume
162,334
Avg. Vol
137,525
52-wk High
$46.12
52-wk Low
$19.72

Latest Key Developments (Source: Significant Developments)

Audentes Therapeutics Announces Public Offering Of Common Stock
Tuesday, 9 Oct 2018 

Oct 9 (Reuters) - Audentes Therapeutics Inc ::AUDENTES THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.AUDENTES THERAPEUTICS INC - INTENDS TO OFFER $150 MILLION OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.  Full Article

Audentes Therapeutics Presents New Positive Interim Data From Aspiro
Friday, 5 Oct 2018 

Oct 5 (Reuters) - Audentes Therapeutics Inc ::AUDENTES THERAPEUTICS PRESENTS NEW POSITIVE INTERIM DATA FROM ASPIRO, THE PHASE 1/2 CLINICAL TRIAL OF AT132 IN PATIENTS WITH X-LINKED MYOTUBULAR MYOPATHY, AT 23RD INTERNATIONAL ANNUAL CONGRESS OF THE WORLD MUSCLE SOCIETY.AUDENTES THERAPEUTICS INC - ALL TREATED PATIENTS CONTINUE TO SHOW MEANINGFUL IMPROVEMENTS IN NEUROMUSCULAR AND RESPIRATORY FUNCTION.AUDENTES THERAPEUTICS INC - AT132 HAS BEEN WELL TOLERATED WITH A MANAGEABLE SAFETY PROFILE TO DATE AT DOSES UP TO 3X10(14) VG/KG.  Full Article

Audentes Therapeutics Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted By The FDA To AT132
Tuesday, 21 Aug 2018 

Aug 21 (Reuters) - Audentes Therapeutics Inc ::AUDENTES ANNOUNCES REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION GRANTED BY THE FDA TO AT132 FOR THE TREATMENT OF X-LINKED MYOTUBULAR MYOPATHY.AUDENTES THERAPEUTICS - PLAN TO MEET WITH FDA TO GAIN ALIGNMENT ON AT132 DEVELOPMENT PLAN.  Full Article

Audentes Therapeutics Reports Qtrly Loss Per Share $0.85
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - Audentes Therapeutics Inc ::AUDENTES THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES UPDATE ON ASPIRO, THE PHASE 1/2 CLINICAL TRIAL OF AT132 IN PATIENTS WITH X-LINKED MYOTUBULAR MYOPATHY.AUDENTES THERAPEUTICS - NO SERIOUS ADVERSE EVENTS IN PATIENTS SINCE LAST UPDATE PROVIDED AT ASGCT IN MAY 2018 IN PHASE 1/2 CLINICAL TRIAL OF AT132.AUDENTES THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.85.  Full Article

Audentes Announces Data From First Dose Cohort Of ASPIRO
Wednesday, 16 May 2018 

May 16 (Reuters) - Audentes Therapeutics Inc ::AUDENTES ANNOUNCES CONTINUING POSITIVE DATA FROM FIRST DOSE COHORT OF ASPIRO, A PHASE 1/2 CLINICAL TRIAL OF AT132 IN PATIENTS WITH X-LINKED MYOTUBULAR MYOPATHY.PATIENT 1 HAS ACHIEVED VENTILATOR INDEPENDENCE AND ORAL FEEDING.SIGNIFICANT IMPROVEMENTS IN NEUROMUSCULAR AND RESPIRATORY FUNCTION AT 24-WEEK TIMEPOINT.HAVE BEEN TOTAL OF 24 ADVERSE EVENTS REPORTED IN ASPIRO, SIX OF WHICH WERE DETERMINED TO BE SERIOUS ADVERSE EVENTS.THERE HAVE BEEN AN ADDITIONAL 11 NON-SERIOUS AES IN ASPIRO, ALL DETERMINED TO BE NOT TREATMENT-RELATED.  Full Article

Audentes Announces Positive Interim Data From First Dose Cohort Of Aspiro
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Audentes Therapeutics Inc ::AUDENTES ANNOUNCES POSITIVE INTERIM DATA FROM FIRST DOSE COHORT OF ASPIRO, A PHASE 1/2 CLINICAL TRIAL OF AT132 IN PATIENTS WITH X-LINKED MYOTUBULAR MYOPATHY.PLANS TO PROVIDE NEXT UPDATE ON INTERIM DATA FROM ASPIRO IN Q2 2018.TOTAL 6 ADVERSE EVENTS (AES) REPORTED IN ASPIRO, 2 OF WHICH WERE DETERMINED TO BE SERIOUS ADVERSE EVENTS (SAES).‍OF FOUR NON-SERIOUS ADVERSE EVENTS, TWO HAVE BEEN DETERMINED TO BE PROBABLY OR POSSIBLY TREATMENT-RELATED​.‍AUDENTES PLANS TO PROVIDE NEXT UPDATE ON INTERIM DATA FROM ASPIRO IN Q2 OF 2018​.  Full Article

Audentes Therapeutics Q3 ‍loss per share $ 0.88​
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Audentes Therapeutics Inc :Audentes Therapeutics reports third quarter 2017 financial results and provides corporate update.Audentes Therapeutics inc qtrly ‍loss per share $ 0.88​.  Full Article

BRIEF-Audentes Announces Data From First Dose Cohort Of ASPIRO

* AUDENTES ANNOUNCES CONTINUING POSITIVE DATA FROM FIRST DOSE COHORT OF ASPIRO, A PHASE 1/2 CLINICAL TRIAL OF AT132 IN PATIENTS WITH X-LINKED MYOTUBULAR MYOPATHY